AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33574076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 32316899 — intervention group
Group type: EXPERIMENTAL
Intervention: Proctosoll Allevia® with controlled diet
Number of subjects: 45
Study 32316899 — intervention group
Group type: COMPARATOR
Intervention: Controlled diet only
Number of subjects: 45
Study 35025156 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture‐moxibustion group
Number of subjects: 120
Study 35025156 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 120
Study 35025156 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion group
Number of subjects: 120
Study 35025156 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 120
Study 32901709 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment group (OAG)
Number of subjects: 78
Study 32901709 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 78
Study 35505455 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framing with proximal temporal framing
Number of subjects: 114
Study 35505455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framing with proximal temporal framing
Number of subjects: 114
Study 35505455 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framing with distal temporal framing
Number of subjects: 114
Study 35505455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framing with distal temporal framing
Number of subjects: 114
Study 35505455 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal framing and gain-loss framing interaction
Number of subjects: 114
Study 34368892 — intervention group
Group type: EXPERIMENTAL
Intervention: gPVG food pattern (general pro-vegetarian food pattern)
Number of subjects: 6439
Study 34368892 — intervention group
Group type: EXPERIMENTAL
Intervention: hPVG food pattern (healthful pro-vegetarian food pattern)
Number of subjects: 6439
Study 34368892 — intervention group
Group type: EXPERIMENTAL
Intervention: uPVG food pattern (unhealthful pro-vegetarian food pattern)
Number of subjects: 6439
Study 35833597 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg)
Number of subjects: 14
Study 35833597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 33217070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pep-Pal (n = 26)
Number of subjects: 56
Study 33217070 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n = 30)
Number of subjects: 56
Study 32433419 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologically-confirmed NASH patients
Number of subjects: 14403
Study 32433419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NASH
Number of subjects: 14403
Study 32469305 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of acetylsalicylic acid (81 mg)
Number of subjects: 48
Study 32469305 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of acetylsalicylic acid (Ecasil-81, 81 mg)
Number of subjects: 48
Study 32469305 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake during administration
Number of subjects: 48
Study 32979027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 300
Study 34119240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans SNZ 1969 (BC)
Number of subjects: 80
Study 34119240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32297840 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximation methods for EVSI
Number of subjects: 0
Study 32297840 — intervention group
Group type: COMPARATOR
Intervention: Traditional Monte Carlo method
Number of subjects: 0
Study 616063739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate or full doses of epirubicin-cyclophosphamide
Number of subjects: 734
Study 616063739 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate and 5-fluorouracil
Number of subjects: 734
Study 35457425 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric acute hypoxia (HYPO)
Number of subjects: 22
Study 35457425 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NORMO)
Number of subjects: 22
Study 34710105 — intervention group
Group type: EXPERIMENTAL
Intervention: Local-ingredients-based supplement (LIBS)
Number of subjects: 324
Study 34710105 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend plus (CSB+)
Number of subjects: 324
Study 32366320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy self-help (MBCT-SH)
Number of subjects: 410
Study 32366320 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy self-help (CBT-SH)
Number of subjects: 410
Study 35325665 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst physical therapy (two PT sessions weekly for 6 weeks)
Number of subjects: 30
Study 35325665 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced physical therapy (one PT session every 2 weeks for 6 months)
Number of subjects: 30
Study 32186653 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin daily
Number of subjects: 15000
Study 32186653 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin daily
Number of subjects: 15000
Study 35897022 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention group (activity tracker wristband, SMS reminders, counselling with diabetes specialist nurse)
Number of subjects: 142
Study 35897022 — intervention group
Group type: COMPARATOR
Intervention: Control group (counselling with diabetes specialist nurse only)
Number of subjects: 142
Study 35897022 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention group
Number of subjects: 142
Study 34190186 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle (CON) method
Number of subjects: 70
Study 34190186 — intervention group
Group type: COMPARATOR
Intervention: Catheter-through-needle (CTN) method
Number of subjects: 70
Study 33977310 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length tibial anatomic axis measurements
Number of subjects: 200
Study 33977310 — intervention group
Group type: COMPARATOR
Intervention: Half-length tibial anatomic axis measurements
Number of subjects: 200
Study 33977310 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of PTS measurements
Number of subjects: 200
Study 33977310 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PTS measurements
Number of subjects: 200
Study 34610846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-app-based instruction
Number of subjects: 0
Study 34610846 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34170477 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver enzymes (ALT)
Number of subjects: 952
Study 34170477 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver enzymes (AST)
Number of subjects: 952
Study 34170477 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT ≥ 40
Number of subjects: 952
Study 34170477 — intervention group
Group type: EXPERIMENTAL
Intervention: AST ≥ 40
Number of subjects: 952
Study 33989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Information Session (IS)
Number of subjects: 604
Study 33989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Information Session with Slideshow
Number of subjects: 604
Study 33989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Information Session followed by Theater
Number of subjects: 604
Study 33989324 — intervention group
Group type: COMPARATOR
Intervention: Informed Consent Form (ICF) only
Number of subjects: 604
Study 35873227 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Psychotherapy (MCP)
Number of subjects: 0
Study 35873227 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 33001764 — intervention group
Group type: COMPARATOR
Intervention: Preoperative capecitabine-based chemoradiation (45-50.4 Gy) followed by six cycles of adjuvant capecitabine without oxaliplatin (control arm)
Number of subjects: 1068
Study 33001764 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative capecitabine-based chemoradiation (45-50.4 Gy) followed by six cycles of adjuvant capecitabine with oxaliplatin (experimental arm)
Number of subjects: 1068
Study 32861275 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS patients
Number of subjects: 39
Study 35561315 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan 25 mg for 4 weeks followed by 100 mg for up to 2 years (cohort 1)
Number of subjects: 13
Study 35561315 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan 50 mg for 4 weeks followed by 200 mg for up to 2 years (cohort 2)
Number of subjects: 13
Study 35561315 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan (both cohorts)
Number of subjects: 13
Study 33243471 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (BioHorizons)
Number of subjects: 60
Study 33243471 — intervention group
Group type: EXPERIMENTAL
Intervention: Group N (NucleOSS)
Number of subjects: 60
Study 33243471 — intervention group
Group type: COMPARATOR
Intervention: Control subgroup (NucleOSS)
Number of subjects: 60
Study 33243471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mm wall thickness subgroup (NucleOSS)
Number of subjects: 60
Study 33177265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dramatic performance by a professional actor, performed for one and half hours once per week for 3 months.
Number of subjects: 34
Study 33177265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dramatic performance).
Number of subjects: 34
Study 33177265 — intervention group
Group type: COMPARATOR
Intervention: Both groups received treatment for BPSD.
Number of subjects: 34
Study 33177265 — intervention group
Group type: COMPARATOR
Intervention: Dramatic performance group vs Control group.
Number of subjects: 34
Study 35105620 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO mental health Gap Action Programme primary care mental health training intervention (10-day training)
Number of subjects: 23
Study 35105620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored training intervention for public health professionals and community representatives
Number of subjects: 23
Study 35105620 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher courses at 3 and 6 months post training
Number of subjects: 23
Study 35105620 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision and monitoring for 1 month pre and post training
Number of subjects: 23
Study 32764111 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma patients
Number of subjects: 0
Study 32764111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCS)
Number of subjects: 0
Study 32764111 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 32764111 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study 34206292 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational program on physical restraint reduction
Number of subjects: 169
Study 34206292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 169
Study 32188768 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training with a VR application and headset to view stereoscopic surgical videos
Number of subjects: 44
Study 32188768 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (control group) including lectures, videos, and skills practice on models
Number of subjects: 44
Study 35499664 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35192438 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote
Number of subjects: 332
Study 35192438 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 332
Study 33888139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam 3 g every 8 hours
Number of subjects: 600
Study 33888139 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 1 g every 8 hours
Number of subjects: 600
Study 32506940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cycling exercise for 12 weeks
Number of subjects: 76
Study 34415265 — intervention group
Group type: EXPERIMENTAL
Intervention: lenadogene nolparvovec (rAAV2/2‐ND4)
Number of subjects: 76
Study 35403225 — intervention group
Group type: EXPERIMENTAL
Intervention: Senicapoc (50 mg enteral) administered as soon as possible after randomization and again after 24 hours.
Number of subjects: 46
Study 35403225 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group).
Number of subjects: 46
Study 35403225 — intervention group
Group type: EXPERIMENTAL
Intervention: Senicapoc (50 mg enteral).
Number of subjects: 46
Study 32722776 — intervention group
Group type: EXPERIMENTAL
Intervention: Component Dorsal Hump Reduction group (CDRg)
Number of subjects: 250
Study 32722776 — intervention group
Group type: EXPERIMENTAL
Intervention: Spare Roof Technique group (SRTg)
Number of subjects: 250
Study 32722776 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (CDRg and SRTg)
Number of subjects: 250
Study 36285404 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted oral naltrexone (50 mg) with weekly counseling for 12 weeks
Number of subjects: 120
Study 33507146 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF-resistant isolates (n=105)
Number of subjects: 195
Study 33507146 — intervention group
Group type: COMPARATOR
Intervention: RIF-sensitive isolates (n=90)
Number of subjects: 195
Study 33507146 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF-resistant/RFB-resistant strains (n=105)
Number of subjects: 195
Study 33507146 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF-resistant/RFB-sensitive strains (n=105)
Number of subjects: 195
Study 33507146 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel deletion mutation (ATCATGCAT) in RIF-resistant strains
Number of subjects: 195
Study 34045905 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg WDTE60N capsule (150 mg curcuminoids)
Number of subjects: 96
Study 34045905 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 96
Study 36363506 — intervention group
Group type: COMPARATOR
Intervention: Custom insole with minimalist flexible shoes (CIG)
Number of subjects: 36
Study 36363506 — intervention group
Group type: COMPARATOR
Intervention: Minimalist flexible shoes alone (SG)
Number of subjects: 36
Study 36363506 — intervention group
Group type: COMPARATOR
Intervention: Custom insole with minimalist flexible shoes (CIG) and Minimalist flexible shoes alone (SG)
Number of subjects: 36
Study 35212740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein and fiber-based multi-ingredient nutritional shake (HPF) (17 g protein, 6 g fiber)
Number of subjects: 206
Study 35212740 — intervention group
Group type: COMPARATOR
Intervention: Low-protein, lower fiber-based placebo (LPF) (1 g protein, 3 g fiber)
Number of subjects: 206
Study 35212740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein and fiber-based multi-ingredient nutritional shake (HPF)
Number of subjects: 206
Study 35212740 — intervention group
Group type: COMPARATOR
Intervention: Low-protein, lower fiber-based placebo (LPF)
Number of subjects: 206
Study 32436641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi)
Number of subjects: 68
Study 35318120 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol with high LH levels on day six
Number of subjects: 109
Study 35318120 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol with low LH levels on day six
Number of subjects: 109
Study 35318120 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol with medium LH levels on day six
Number of subjects: 109
Study 35318120 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 109
Study 36273991 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-oral pancreatoscopy-guided lithotripsy (POP)
Number of subjects: 150
Study 36273991 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 150
Study 35405168 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd/ChAd/BNT162b2 (Pfizer-BioNtech)
Number of subjects: 2422
Study 35405168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (Janssen)
Number of subjects: 2422
Study 35405168 — intervention group
Group type: COMPARATOR
Intervention: BNT (15 μg)
Number of subjects: 2422
Study 35405168 — intervention group
Group type: COMPARATOR
Intervention: BNT/BNT
Number of subjects: 2422
Study 32772737 — intervention group
Group type: COMPARATOR
Intervention: Oral medications (including voltage‐gated calcium channels antagonists, voltage‐gated sodium channel antagonists, serotonin‐norepinephrine reuptake inhibitors, NMDA antagonists)
Number of subjects: 0
Study 32772737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37349498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/Paracetamol 1000 mg
Number of subjects: 200
Study 37349498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/Paracetamol 1000 mg/Codeine 60 mg
Number of subjects: 200
Study 37349498 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg/Codeine 60 mg
Number of subjects: 200
Study 37349498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 34432989 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Early Learning (AEL) intervention
Number of subjects: 0
Study 34432989 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33141092 — intervention group
Group type: EXPERIMENTAL
Intervention: DHealthBar mobile-based intervention (WeChat applet)
Number of subjects: 79
Study 33141092 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials
Number of subjects: 79
Study 35397474 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical harms warning message
Number of subjects: 623
Study 35397474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung harms warning message
Number of subjects: 623
Study 35397474 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 harms warning message
Number of subjects: 623
Study 35397474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine addiction warning message
Number of subjects: 623
Study 35397474 — intervention group
Group type: COMPARATOR
Intervention: Control (messages about vape litter)
Number of subjects: 623
Study 33295397 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus Plantarum probiotic
Number of subjects: 0
Study 33295397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 36501014 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine plus vitamin C
Number of subjects: 50
Study 36501014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32740409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg once daily, n=9)
Number of subjects: 16
Study 32740409 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5 mg once daily, n=7)
Number of subjects: 16
Study 32740409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg once daily)
Number of subjects: 16
Study 32740409 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren and Ramipril
Number of subjects: 16
Study 32881865 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated materials
Number of subjects: 0
Study 32881865 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34244257 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially covered self-expandable metal stent (PCSEMS)
Number of subjects: 100
Study 34244257 — intervention group
Group type: COMPARATOR
Intervention: Uncovered self-expandable metal stent (USEMS)
Number of subjects: 100
Study 32943383 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal clavicle resection (DCR) during arthroscopic rotator cuff repair
Number of subjects: 200
Study 615916899 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses
Number of subjects: 117
Study 615916899 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 117
Study 35943324 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional double‐puncture arthrocentesis
Number of subjects: 26
Study 35943324 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐puncture type 2 arthrocentesis
Number of subjects: 26
Study 33112363 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mobile cardiac rehabilitation (MCR) for 6 months with telemonitoring and coaching based on motivational interviewing
Number of subjects: 179
Study 33112363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cardiac rehabilitation)
Number of subjects: 179
Study 33112363 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mobile cardiac rehabilitation (MCR)
Number of subjects: 179
Study 32174633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit endodontic therapy
Number of subjects: 65
Study 32174633 — intervention group
Group type: COMPARATOR
Intervention: Multiple-visit endodontic therapy
Number of subjects: 65
Study 32552530 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter yoga (LY) twice weekly for 8 weeks
Number of subjects: 66
Study 32552530 — intervention group
Group type: COMPARATOR
Intervention: Routine daily activities (Control)
Number of subjects: 66
Study 33165588 — intervention group
Group type: EXPERIMENTAL
Intervention: Public primary health centres
Number of subjects: 60
Study 33165588 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn care and immunization services
Number of subjects: 60
Study 33165588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health services
Number of subjects: 60
Study 33165588 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-communicable disease (NCD) service readiness
Number of subjects: 60
Study 33165588 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of medicines and supplies for communicable diseases
Number of subjects: 60
Study 33165588 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of medicines and supplies for maternal health services
Number of subjects: 60
Study 33165588 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic equipment availability
Number of subjects: 60